Aarhus University Seal / Aarhus Universitets segl

Statin use and risk of contralateral breast cancer: a nationwide cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Rikke Langballe, Danish Cancer Society Research Center, Denmark
  • Deirdre Cronin Fenton
  • Christian Dehlendorff, Danish Cancer Society Research Center, Denmark
  • Maj-Britt Jensen, Rigshospitalet, Denmark
  • Bent Ejlertsen, h Department of Oncology, Rigshospitalet , Copenhagen , Denmark.
  • ,
  • Michael Andersson, Rigshospitalet, Denmark
  • Søren Friis, Danish Cancer Society Research Center, University of Copenhagen, Denmark
  • Lene Mellemkjær, Danish Cancer Society Research Center, Denmark

BACKGROUND: Statins have demonstrated antineoplastic effects in breast cancer cell lines, particularly in oestrogen receptor (ER)-negative cell lines. However, epidemiological studies have not supported a preventive effect of statin use against breast cancer. Therefore, we examined the association between statin use and contralateral breast cancer (CBC) risk among women with breast cancer.

METHODS: We identified 52,723 women with non-metastatic breast cancer during 1996-2012 from the Danish Breast Cancer Group database. We defined time-varying post-diagnosis statin use as minimum two prescriptions lagged by 1 year. Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with statin use.

RESULTS: Statin use was associated with a lower CBC risk (HR = 0.88; 95% CI = 0.73-1.05). The inverse association was strongest for long-term use overall (HR = 0.64; 95% CI = 0.43-0.96), although the HR specifically for long-term consistent use and high-intensity use approached unity. Among ER-negative breast cancer patients, statin use was associated with a CBC risk reduction (HR = 0.67; 95% CI = 0.45-1.00).

CONCLUSIONS: We found some indication that statins reduce the risk of CBC. Further evaluations are needed to disentangle the equivocal results for long-term use and to establish if ER-negative breast cancer patients may benefit most from statin use.

Original languageEnglish
JournalBritish Journal of Cancer
Pages (from-to)1297-1305
Number of pages9
Publication statusPublished - 2018

See relations at Aarhus University Citationformats

ID: 140546341